Linda Rubinstein

Linda Rubinstein is Adverum’s chief financial officer responsible for the company’s financial strategy and accounting functions, including financial planning and analysis and select other functions. Ms. Rubinstein has 35 years of experience in investment banking and chief financial officer roles in life science, SaaS and other companies. She currently serves as a partner at FLG Partners, where she assists clients with strategic planning, executes financing transactions, creates business plans and develops corporate and investor positioning. Over the past two decades, Ms. Rubinstein has served as consulting chief financial officer and financial advisor to multiple biotechnology companies. Prior to her career in biotechnology, Ms. Rubinstein served as senior vice president at Lehman Brothers executing mergers and acquisitions, public and private equity, debt and restructuring transactions for clients in the life sciences, healthcare and industrial sectors.

Ms. Rubinstein earned her B.A. and an M.A. from the University of California, Los Angeles.

Ms. Rubinstein currently serves on the board of directors of Biocept, Inc., a medical diagnostic company.

Location

San Francisco, United States

Links

Previous companies


Org chart


Teams


Offices

This person is not in any offices


Adverum Biotech

9 followers

Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.


Industries

Employees

51-200

Links